2.3. Data Collection

Data collected were baseline demographics (age and gender), cancer type and disease stage, treatment intent (curative or palliative), and chemotherapy regimen (monotherapy or polytherapy). The CGAs included the Timed Up and Go (TUG) [³⁷], history of falls in the last 6 months (yes or no), and number of concomitant medications. Nutrition was assessed using the mini nutritional assessment (MNA) [^38,39] and scores were interpreted as malnutrition (0–7), at risk of malnutrition (8–11), and normal (12–14). Body mass index was recorded. Depression was screened for using the 15-item Geriatric Depression Scale (GDS-15) [⁴⁰], with scores ≤ 5 considered normal and scores of >5 suggested depression. We collected scores of Katz Activities of Daily Living (ADL) with scores between 0–6 (0 very dependent and 6 independent) [⁴¹], Lawton Instrumental ADL, a summary score ranges from 0 (low function, dependent) to 9 (high function, independent), and Eastern Cooperative Oncology Group (ECOG) Performance Status [⁴²]. Comorbidities were collected using the Charlson Comorbidity Index [⁴³] and quantified as mild (1–2); moderate (3–4); and severe (≥5). Cognitive assessment was performed using the Mini-cog test [³³] or 6CIT [⁴⁴]. If impairments were noted, then patients proceeded to a Montreal Cognitive Assessment (MOCA) [⁴⁵]. Results were divided into cognitive impairment or no impairment. The results of chemotherapy toxicity risk, estimated using the Cancer Aging and Research Group (CARG) calculator [³⁴], were categorized into low (0–5), intermediate (6–9), and high (≥10) risk. The rates of baseline chemotherapy dose reduction were collected. This was recorded in the GOAL database. We identified subsequent dose reductions (defined as any reduction from baseline dose), dose delays, treatment discontinuations, or unscheduled hospitalizations as surrogates of treatment toxicity. The chemotherapy pharmacy compounding unit provided data on dose delays, dose reductions during treatment, and treatment discontinuation. Reasons for discontinuation and hospitalizations were collected from retrospective review of patient records. We opted to use these outcomes as opposed to the NCI-CTCAE Grade 3–5 toxicity to ensure accuracy of reporting, where all grade 3 toxicity not requiring hospitalization may not be captured retrospectively.